About Ergomed

Ergomed begins

Clinical investigator Dr. Miroslav Reljanović founds Ergomed in Zagreb, Croatia.

First co-development deal

Dr. Reljanovic successfully introduces an innovative co-development business model to support clinical programs across Europe.

PrimeVigilance launches

Well-known international drug safety expert, Elliot Brown, and Dr. Reljanović form PrimeVigilance, which aims to be a leading specialist in pharmacovigilance services.

Ergomed IPO

Ergomed is successfully added to the AIM market of the London Stock Exchange and trades under the symbol ERGO.

Aquisiton of Sound Opinion

Ergomed acquires Sound Opinion, a medical information service company, to bolster the PrimeVigilance offering.

Acquisition of Haemostatix

Ergomed acquires Nottingham-based Haemostatix to access its proprietary technology and pipeline products PeproStat™ and ReadyFlow™.

Acquisition of O+P, GASD

German-based CRO company, O+P, and GASD, a biostatistics company, is acquired to bolster Ergomed’s full-service offering.

Acquisition of PharmInvent

Ergomed acquires leading pharmacovigilance and regulatory services business, PharmInvent.

Acquisition of PSR

Ergomed acquires PSR Group BV, a specialist orphan drug CRO, to further enhance its expertise in rare diseases.

Acquisition of Ashfield PV

Ashfield Pharmacovigilance, a US-based specialist pharmacovigilance services provider, is acquired to increase our support for US clients.

Acquisition of MedSource

Ergomed acquires MedSource, an award-winning, oncology-focused US-based CRO to further grow our footprint in the US.

Acquisition of ADAMAS

Ergomed acquires ADAMAS, a leading global regulatory compliance provider.

Permira completes acquisition of Ergomed

Ergomed strongly positioned for future growth in new partnership with Permira

Acquisition of Panacea

Ergomed acquired Panacea, a company based in the Isle of Man, British Isles.